Clinical Takeaway Plant-derived cannabidiol (CBD) oral solution produced meaningful reductions in drop seizures in patients with Lennox-Gastaut syndrome even at thresholds below the standard 50% benchmark used in clinical trials. Caregiver-reported outcomes...
Cannabidiol for Lennox-Gastaut: Clinical Trial Evidence
Clinical Takeaway Pharmaceutical-grade cannabidiol (Epidiolex) reduced drop seizure frequency in Lennox-Gastaut syndrome patients at thresholds below the traditional 50% benchmark, with caregiver-reported outcomes confirming that even smaller reductions translated to meaningful real-world...
Cannabidiol for Lennox-Gastaut: Cannabinoid Clinical Trials
Clinical Takeaway Plant-derived cannabidiol (CBD) oral solution produced meaningful reductions in drop seizures in patients with Lennox-Gastaut syndrome at thresholds below the traditional 50% benchmark used in clinical trials. Caregiver-reported outcomes aligned...
Cannabidiol for Lennox-Gastaut: Clinical Trial Evidence
Clinical Takeaway Plant-derived cannabidiol (CBD) oral solution produced meaningful reductions in drop seizures in patients with Lennox-Gastaut syndrome at thresholds below the conventional 50% benchmark used in clinical trials. Caregiver-reported outcomes aligned...